Skip to content
Study details
Enrolling now

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001

Iovance Biotherapeutics, Inc.
NCT IDNCT05361174ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

53

Study length

about 4.9 years

Ages

18–70

Locations

10 sites in CA, FL, KS +5

What this study is about

This trial is testing a treatment called IOV-4001 in adults with melanoma or advanced non-small cell lung cancer. The goal is to see if this treatment is effective and safe.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive IOV-4001

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Phase 2: Objective Response Rate (ORR)

Secondary: CR Rate, Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), Progression-free Survival (PFS), Safety and Tolerability of IOV-4001

Body systems

Oncology